EVGN Stock Overview
Operates as a computational biology company. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Evogene Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪4.72 |
| 52 Week High | ₪37.00 |
| 52 Week Low | ₪4.50 |
| Beta | 1.14 |
| 1 Month Change | -22.24% |
| 3 Month Change | -53.40% |
| 1 Year Change | -85.10% |
| 3 Year Change | -91.34% |
| 5 Year Change | -91.44% |
| Change since IPO | -95.93% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate
Mar 05
Will Evogene (TLV:EVGN) Spend Its Cash Wisely?
Oct 09Will Evogene (TLV:EVGN) Spend Its Cash Wisely?
Jun 26We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate
Mar 13Here's Why We're Watching Evogene's (TLV:EVGN) Cash Burn Situation
Oct 07We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate
Jun 16Will Evogene (TLV:EVGN) Spend Its Cash Wisely?
Mar 02Here's Why We're Not Too Worried About Evogene's (TLV:EVGN) Cash Burn Situation
May 28Companies Like Evogene (TLV:EVGN) Are In A Position To Invest In Growth
Jan 21
What Can We Make Of Evogene's (TLV:EVGN) CEO Compensation?
Nov 30Shareholder Returns
| EVGN | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | -8.4% | -0.6% | -0.5% |
| 1Y | -85.1% | -24.8% | 23.0% |
Return vs Industry: EVGN underperformed the IL Biotechs industry which returned -24.8% over the past year.
Return vs Market: EVGN underperformed the IL Market which returned 23% over the past year.
Price Volatility
| EVGN volatility | |
|---|---|
| EVGN Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IL Market | 8.0% |
| 10% least volatile stocks in IL Market | 3.0% |
Stable Share Price: EVGN's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: EVGN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 142 | Ofer Haviv | www.evogene.com |
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Evogene Ltd. Fundamentals Summary
| EVGN fundamental statistics | |
|---|---|
| Market cap | ₪32.03m |
| Earnings (TTM) | -₪85.58m |
| Revenue (TTM) | ₪27.22m |
1.2x
P/S Ratio-0.4x
P/E RatioIs EVGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVGN income statement (TTM) | |
|---|---|
| Revenue | US$7.48m |
| Cost of Revenue | US$2.33m |
| Gross Profit | US$5.15m |
| Other Expenses | US$28.67m |
| Earnings | -US$23.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.46 |
| Gross Margin | 68.90% |
| Net Profit Margin | -314.43% |
| Debt/Equity Ratio | 0% |
How did EVGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 13:32 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Evogene Ltd. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Benjamin Haynor | Alliance Global Partners |
| Kristen Kluska | Cantor Fitzgerald & Co. |